 CinCor Pharma NASDAQ: CINC has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat CIN-107 for the treatment of patients with uncontrolled hypertension and chronic kidney disease CKD. The figHTN-CKD trial is a randomised Phase 2 clinical trial. 